
The drugmaker behind Ozempic and Wegovy has cut its sales and profit targets in the face of intense competition from other weight-loss and diabetes treatments.
Novo Nordisk warned over weaker-than-expected profits amid the recent growth of US rival Eli Lilly’s Mounjaro and Zepbound injection treatments.